Trichosanthin suppresses the proliferation of glioma cells by inhibiting LGR5 expression and the Wnt/β-catenin signaling pathway.

Studies have indicated that trichosanthin (TCS), a bioactive protein extracted and purified from the tuberous root of Trichosanthes kirilowii (a well‑known traditional Chinese medicinal plant), produces antitumor effects on various types of cancer cells. However, the effects of TCS on glioma cells are poorly understood. The objective of this study was to investigate the antitumor effects of TCS on the U87 and U251 cell lines. The in vitro effects of TCS on these two cell lines were determined using a Cell Counting Kit‑8 (CCK‑8) assay, Annexin V‑FITC staining, DAPI staining, Transwell assays, terminal deoxynucleotidyl transferase‑mediated dUTP nick end‑labeling (TUNEL) assays, 5,5',6,6'‑tetrachloro‑1,1',3,3'‑tetraethyl‑imidacarbocyanine iodide (JC‑1) staining and western blotting, which was utilized to assess the expression of leucine‑rich repeat‑containing G protein‑coupled receptor 5 (LGR5) and key proteins in the Wnt/β‑catenin signaling pathway. Our data indicated that TCS inhibited the proliferation of glioma cells in a dose‑ and time‑dependent manner and played a role in inhibiting glioma cell invasion and migration. Additional investigation revealed that the expression levels of LGR5 and of key proteins in the Wnt/β‑catenin signaling pathway were markedly decreased after TCS treatment. The results suggest that TCS may induce apoptosis in glioma cells by targeting LGR5 and repressing the Wnt/β‑catenin signaling pathway. In the future, in vivo experiments should be conducted to examine the potential use of this compound as a novel therapeutic agent for gliomas.

Introduction

Primary central nervous system tumors account for ~2% of human malignancies (1). In general, malignant glioma is the most common type of primary intracranial tumor, and the incidence of malignant glioma is increasing worldwide, primarily as a result of improvements in diagnostic imaging (2). Despite the comprehensive treatment regimen of surgery, radiotherapy and chemotherapy, resistance to standard anti-proliferative treatment with concomitant radiotherapy and chemotherapy is common and manifests as an invasive cell population that leads to tumor recurrence and death (3). Therefore, there is an urgent need for the development of a novel agent displaying glioma-specific toxicity.

Trichosanthin (TCS), a protein of ~27 kDa that is extracted from the Chinese herb Trichosanthes kirilowii Maxim, is a type I ribosome-inactivating protein (RIP) (4,5). It has been used for centuries in China as an abortifacient during early pregnancy (6). Many studies have shown that TCS has enormous potential as a therapeutic drug due to its suppression of the proliferation of various cancer cell types. Research has demonstrated that TCS restricts human choriocarcinoma cell proliferation by inducing reactive oxygen species (ROS) production (7,8). In addition, TCS suppresses the proliferation of HeLa cells by blocking the PKC/MAPK signaling pathway (9) and induces the apoptosis of cervical cancer cells by increasing the intracellular Ca2+ concentration (10) and by regulating the expression of Smac (11). Moreover, previous studies have shown that TCS suppresses the proliferation of breast cancer cells and HepA-H cells by inducing cell cycle arrest and promoting apoptosis (12–14). Furthermore, research suggests that TCS induces the apoptosis of chronic myeloid leukemia cells via endoplasmic reticulum stress, the mitochondrial-dependent apoptosis pathway and the inhibition of PKC (15,16). Studies have also revealed that TCS displays anti-HIV activity, as TCS is cytotoxic to HIV-infected macrophages and lymphocytes and decreases viral replication (17,18). Recently, a new study showed that a peptide derived from TCS suppresses the immune response by activating CD8+CD28− regulatory T cells and serves as a potential therapeutic agent for immunological diseases (19). TCS not only has inhibitory activity against various tumor cells but also shows inhibitory activity against several normal somatic cell types, including proximal tubule epithelial cells, hepatocytes and antigen-specific T cells (20–22). Previous studies have reported that TCS can cause neurological reactions in HIV-infected patients and that such toxicity may be due to the effect of TCS on HIV-infected macrophages (23). However, intravenous injections of TCS had no toxic effects on normal mouse brain or pituitary cells (24). In conclusion, since TCS displays anticancer activity in various malignant tumors, we aimed to determine whether TCS exerts antitumor effects on glioma cells. Here, we demonstrated the anti-proliferative effects and antitumor mechanisms of action of TCS on glioma cells. Our results suggest that TCS is a novel chemotherapeutic agent that may target leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) and the Wnt/β-catenin pathway in human glioma cells.

Materials and methods

Materials

High glucose DMEM containing fetal bovine serum (FBS), penicillin G and streptomycin was purchased from Gibco (Carlsbad, CA, USA). The U87 and U251 human malignant glioma cell lines were provided by the China Infrastructure of Cell Line Resources, (Beijing, China). TCS was purchased from Shanghai Jinshan Pharmaceutical (Shanghai, China). The primary antibodies against LGR5, β-catenin, GSK-3β, c-myc and cyclin D1 used for western blot analysis were provided by Santa Cruz Biotechnology (Santa Cruz, CA, USA). The other reagents used in this study were of analytical grade.

Cell culture

The U87 and U251 human malignant glioma cell lines were cultured in high glucose DMEM containing 1% antibiotics and 10% FBS. The cells were cultured in an incubator at 37°C in 5% CO2 and a humidified atmosphere.

Cell morphology

U87 and U251 cells were grown in culture flasks to the logarithmic growth phase. Then, the cells were treated with TCS (20 µM). Morphological changes in the cells were observed using an inverted microscope, and the cells were photographed after treatment for 24 h.

Cell viability assay

A Cell Counting Kit-8 (CCK-8) (Dojindo, Japan) assay was utilized to evaluate cell viability. U87 and U251 cells were resuspended in complete or serum-free medium at a density of 1×104 or 5×103 cells/well and were cultured in 96-well plates. The cell samples were exposed to various concentrations (2.5, 5, 10, 20, 40 or 80 µM) of TCS for 24, 48 or 72 h. After TCS treatment, the medium was removed from each well, 10 µl of CCK-8 and 100 µl of serum-free medium were added, and the cells were incubated for 1 h at 37°C. A microplate reader was used to measure the absorbance of each well at 450 nm.

Detection of apoptosis via flow cytometry

The apoptosis of U87 and U251 cells was analyzed using an Annexin V-FITC apoptosis detection kit (Sigma-Aldrich, St. Louis, MO, USA). The cells were cultured with TCS (10, 20 µM) or vehicle (PBS) for 24 h, and then, the cells were harvested at a density of 1×106 cells/ml. The cells were washed twice with ice-cold PBS. Then, the cells (1×106) were resuspended in 195 µl of binding buffer, and 5 µl of Annexin V-FITC and propidium iodide (PI) were added to the cell suspension; subsequently, the cells were covered in aluminum foil and incubated at room temperature for 20 min. After this incubation, apoptosis was analyzed via flow cytometry.

DAPI staining

After U87 glioma cells were treated with TCS (10 or 20 µM) or PBS for 24 h, they were fixed in 4% formaldehyde and washed three times with PBS. Then, the cells were stained with DAPI staining solution (10 µg/ml) for 5 min and washed three times with PBS. The morphologic changes in the nuclei were detected using a fluorescence microscope.

Mitochondrial membrane potential measurement based on 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-imidacarbocyanine iodide (JC-1) staining

The decrease in mitochondrial membrane potential, which is a hallmark of apoptosis, was detected using a JC-1 mitochondrial membrane potential assay kit (Cayman Chemical, Ann Arbor, MI, USA). U87 glioma cells were treated with TCS (10 or 20 µM) or PBS for 24 h and then incubated in 1 ml of JC-1 working solution for 30 min at 37°C in an incubator. These cells were washed twice with ice-cold PBS, and the fluorescence intensity of the cells was then observed via fluorescence microscopy. Decreased fluorescence of the cells was observed as the mitochondrial membrane potential collapsed.

Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay

DNA fragmentation was detected using a One-Step TUNEL kit (Abnova Corporation, Taipei City, Taiwan) according to the manufacturer's instructions. Briefly, after treatment with TCS (10 or 20 µM) or PBS, U87 cells were fixed in 4% paraformaldehyde for 30 min at room temperature. Then, the cells were washed three times with PBS and permeabilized for 2 min on ice. Next, the cells were resuspended in TUNEL working solution and incubated in a humidified atmosphere shielded from light for 1 h at 37°C. Green fluorescence was detected in the FITC-labeled TUNEL-positive cells under a fluorescence microscope.

Cell migration and invasion assays

Wound healing assays were used to assess the effects of TCS on glioma cell migration. U87 cells were seeded in culture plates and incubated until they reached confluency. Subsequently, a scratch was made on the cell surface using a 10-µl pipette tip. The cells were washed with PBS and treated with TCS (5 µM) or PBS for 24 h. The width of the wound was photographed under a microscope at 0 and 24 h. In addition, the effect of TCS on glioma cell invasion was determined using Matrigel-coated Transwell assays. U87 cells were treated with DMEM containing TCS (5 µM) or PBS for 24 h. Then, the cells were trypsinized and seeded into the upper chamber of a Transwell insert at a density of 1×105. Medium containing 20% FBS was added to the lower chamber, and the cells were cultured for 24 h. The cells that invaded into the outer surface of the Transwell insert were stained with 0.5% crystal violet solution and counted using an inverted microscope.

Western blot analysis

Cellular proteins were extracted from glioma cells using lysis buffer [1 mM EDTA (pH 8.0), 50 mM Tris (pH 7.4), 150 mM NaCl, 1% NP-40, 0.1% SDS, and 0.5% sodium deoxycholate] according to the manufacturer's instructions for western blot analysis. A bicinchoninic acid protein quantitation kit (BioVision, Palo Alto, CA, USA) was used to measure the protein concentrations. The same amounts of whole-cell protein extracts from each sample were separated via SDS-PAGE and transferred to a PVDF membrane with a pore size of 0.2 µm. Subsequently, the membrane was blocked with 5% milk in TBS-T for 1 h at room temperature (RT), incubated in a primary antibody overnight at 4°C, and then incubated in a horseradish peroxidase-conjugated secondary antibody at room temperature for 2 h. After washing three times with TBS, the immunoreactive bands were detected using a gel imaging analysis system after applying a chemiluminescence working solution to the PVDF membrane according to the manufacturer's instructions.

Statistical analysis

SPSS version 19.0 was utilized for the statistical analyses, and the data are presented as the mean ± standard deviation (SD) of multiple independent experiments. Student's t-test and ANOVA were used to evaluate the differences between the means, and P<0.05 was considered to indicate a statistically significant difference.

Results

The CCK-8 assay was used to evaluate the impact of TCS on glioma cell viability. U87 and U251 cells were treated for 24 h with TCS diluted to concentrations of 2.5, 5, 10, 20, 40 and 80 µM in complete medium; the assay results indicated that relative to the control cells, U87 cells exhibited viabilities of 95.4, 93.8, 85.9, 62.2, 44.1 and 36.2%, respectively, and U251 cells exhibited viabilities of 99.9, 92.1, 88.3, 68.8, 62.7 and 56%, respectively (n=4; P<0.05) (Fig. 1A). In addition, the IC50 values for U87 and U251 were 40 and 51.6 µM, respectively. We analyzed the change in cell viability of U87 cells after treatment with TCS concentrations of 2.5, 5, 10, 20, 40 and 80 µM in serum-free medium; compared with the control cells treated with PBS alone, U87 cells treated for 24 h exhibited viabilities of 97.7, 88.7, 78.6, 62.1, 36.2 and 27.3%, respectively, U87 cells treated for 48 h exhibited viabilities of 94.2, 82.3, 71.8, 47.8, 26.9 and 19.0%, respectively and U87 cells treated for 72 h exhibited viabilities of 86.3, 67.7, 47.3, 28.4, 17.0 and 7.9%, respectively (n=4; P<0.05) (Fig. 1B). The IC50 values of U87 cells for 24, 48 and 72 h of TCS treatment were 30.2, 20.5 and 10.0 µM, respectively. The assay results indicated that in both the presence and the absence of serum, TCS inhibited the viability of glioma cells in a dose- and time-dependent manner.

Figure 1

TCS inhibits the viability of glioma cells in a dose- and time-dependent manner. (A) Human malignant glioma cells (U87 and U251) were cultured in serum-containing DMEM in the presence of different concentrations of TCS (0–80 µM) for 24 h. The CCK-8 assay was used to determine cell viability. The data are presented as the mean ± SD of three independent experiments. *P<0.05 compared with the PBS-treated (control) group. (B) U87 cells were cultured in serum-free DMEM containing various concentrations of TCS (0–80 µM) for different periods (24, 48 or 72 h). Glioma cell viability was investigated using the CCK-8 assay. The data are presented as the mean ± SD of three independent experiments. *P<0.05 compared with the control group. (C) U87 and U251 cells were cultured in cell culture dishes and treated with DMEM containing TCS (20 µM) or PBS for 24 h. After treatment, the morphological changes in the glioma cells were observed via microscopy. Representative images from three independent experiments are shown.

TCS induces the apoptosis of glioma cells

To determine whether the induction of glioma cell apoptosis is related to the inhibition of proliferation, the apoptosis rate was analyzed via flow cytometry after labeling cells with Annexin V-FITC/PI. As indicated in Fig. 2, the apoptotic percentages of the U87 and U251 cells were 5.9 and 5.1%, respectively, in the PBS-treated group; 14.1 and 10.4%, respectively, in the group treated with 10 µM of TCS and 36.1 and 27.8%, respectively, in the group treated with 20 µM of TCS. Moreover, DAPI staining was used to observe morphological variations in the nuclei, and the data showed that chromatin condensation and fragmented nuclei which are typical characteristics of apoptosis, were detected following DAPI staining when U87 cells were treated with 10, 20 µM TCS for 24 h (Fig. 3A). Results also showed that the number of TUNEL-positive U87 cells was significantly increased in the TCS-treated group compared with the PBS treated group (Fig. 3B). Furthermore, JC-1 staining was used to visualize mitochondrial depolarization in glioma cells treated with TCS. The mitochondria of untreated JC-1-stained U87 cells emitted faint green fluorescence and strong orange–red fluorescence, whereas the apoptotic cells emitted green fluorescence. Compared with the control cells treated with PBS, TCS-treated U87 cells exhibited significantly decreased mitochondrial membrane potentials, as evidenced by these cells' distinct green fluorescence (Fig. 3C).

Figure 2

Analysis of apoptosis via Annexin V/PI staining. U87 cells were cultured in DMEM and were treated with TCS (10, 20 µM) or vehicle (PBS) for 24 h. The cells were analyzed via flow cytometry after staining with Annexin V/PI. The percentage of apoptotic cells (right lower quadrant, early apoptotic cells; right upper quadrant, late apoptotic cells) was analyzed using CellQuest Pro software. Lower graphs show the percentage of apoptotic or dead cells. *P<0.05 compared to the respective PBS-treated (control) cells. The data are presented as the mean ± SD of three independent experiments.

Figure 3

TCS induces apoptosis in glioma cells. (A) U87 cells were cultured in DMEM containing TCS (10, 20 µM) or PBS for 24 h, and changes in nuclear morphology were observed via DAPI staining and fluorescence microscopy. The experiment was repeated three times, and the images are representative. (B) Apoptotic cells were detected via TUNEL staining. U87 cells were treated as described above prior to TUNEL staining. The number of TUNEL-positive cells was significantly increased due to TCS treatment. Representative images of TUNEL staining are shown. (C) The mitochondrial membrane potential of glioma cells was decreased due to TCS treatment. U87 cells were treated with TCS (10, 20 µM) or PBS for 24 h, and the decrease in the mitochondrial membrane potential was observed based on JC-1 staining via fluorescence microscopy. The images are representative of three independent experiments.

TCS inhibits glioma cell migration and invasion

Wound healing and Matrigel-coated Transwell assays were used to evaluate the effect of TCS on migration and invasion. The percentage of wound repair decreased from 61.52 to 36.87% in response to TCS, and the ratio of invading cells on the lower side of the membrane was 42.57% after treatment with 5 µM TCS compared with the control (set to 100%; Fig. 4).

Figure 4

TCS inhibits glioma cell migration and invasion in vitro. The effects of TCS on U87 cell migration were assessed using wound healing assays. (A) Representative images of wound healing at 0 and 24 h. (B) Quantification of the wound healing assays after U87 cells were treated with TCS (5 µM) or vehicle (PBS) for 0 and 24 h. *P<0.05. Matrigel-coated Transwell assays were used to analyze U87 cell invasion. (C) Representatives images of cells that migrated through the Matrigel-coated Transwell inserts. (D) Histogram indicating the percentage of invasive cells compared with the control group. *P<0.05.

TCS inhibits the expression of LGR5 and key proteins in the Wnt/β-catenin signaling pathway in glioma cells

Studies have shown that LGR5 and the Wnt/β-catenin signaling pathway play crucial roles in the proliferation, differentiation and metastasis of cancers of varying origin (25). To further explore the suppressive mechanism of action of TCS in glioma cells, we examined the expression levels of LGR5 by immunoblotting. As shown in Fig. 5, as the TCS dose increased (0–20 µM; 24 h), the levels of LGR5 protein expression in the U87 cells markedly decreased. We also analyzed the protein levels of phosphorylated glycogen synthase kinase-3β (pGSK-3βser9), β-catenin, c-myc and cyclin D1, which are key members of the Wnt/β-catenin signaling pathway, via western blot analysis, and we found that increasing concentrations of TCS (0–20 µM; 24 h) resulted in an evident downregulation of these proteins (Fig. 5). Taken together, these results demonstrated that TCS treatment reduces the expression of LGR5 and key proteins in the Wnt/β-catenin signaling pathway in a dose-dependent manner in glioma cells.

Figure 5

Western blot analysis of LGR5 and Wnt/β-catenin signaling pathway proteins. U87 cells were treated with different concentrations of TCS (5, 10, or 20 µM) or vehicle (PBS) for 24 h. Protein samples were obtained from the four groups and were analyzed via western blot analysis. The results showed that the protein levels of LGR5 and key members of the Wnt/β-catenin signaling pathway (pGSK-3βSer9, β-catenin, c-myc and cyclin D1) were downregulated in response to increasing TCS concentrations. Right panel, quantitative analysis of protein expression from three independent experiments. *P<0.05 compared with the control group.

Discussion

Malignant gliomas account for the majority of primary brain tumors (26). The development of neuroimaging has allowed for the early diagnosis of these gliomas, and standard treatment with surgery, chemotherapy and radiation can be provided; however, patients with malignant gliomas nonetheless have poor prognoses. According to research data, the median survival duration for malignant glioma patients after treatment is less than one year (27). Therefore, neurosurgical studies of malignant gliomas have long focused on finding more effective treatment approaches. As a newly discovered active constituent of natural products, TCS has drawn a great deal of research attention due to its antitumor effects. In the present study, we demonstrated for the first time that TCS produces anti-glioma effects by inhibiting cell viability, migration, and invasion and by inducing apoptosis. Our results revealed that TCS significantly inhibited the proliferation of the U87 and U251 cell lines, which contain large numbers of glioma stem cells, in a dose- and time-dependent manner. The IC50 values for U87 cells were lower than the corresponding IC50 values for U251 cells, indicating that U87 cells were more vulnerable than U251 cells to TCS. Therefore, U87 cells were selected for additional experimentation.

Prior research has demonstrated that inducing apoptosis in tumor cells is an important mechanism of action for many antitumor drugs. In our study, flow cytometry revealed that apoptosis occurred in glioma cells after TCS treatment. Consistent with this finding, different typical morphological characteristics of apoptotic cells, including the condensation and clustering of chromatin along the nuclear membrane, internucleosomal DNA fragmentation and a decrease in mitochondrial membrane potential, were detected in the TCS-treated U87 cells by DAPI staining, a TUNEL assay, and JC-1 staining, respectively. These results suggest that TCS inhibits the proliferation of malignant glioma cells by inducing apoptosis.

However, the mechanism by which TCS induces apoptosis in malignant glioma cells has not been well established. LGR5, a member of the G protein-coupled receptor family (28), plays an important role in embryonic development and is widely expressed in brain and spinal cord tissue (29,30). Recent studies have revealed that the overexpression of LGR5 promotes the survival and growth of different types of tumors, including colorectal carcinomas, Ewing's sarcomas and glioblastomas (31–33). Furthermore, in our previous research, we found that LGR5 expression was closely associated with the pathologic grade of gliomas; moreover, the knockdown of LGR5 was found to inhibit the proliferation of U87 cells and suppresses the growth of xenografts (34). In the present study, our findings demonstrated that TCS treatment significantly reduce the levels of LGR5, pGSK-3βSer9, β-catenin, c-myc and cyclin D1 in the U87 cells. It has been well established that LGR5, pGSK-3βSer9, β-catenin, c-myc and cyclin D1 are important proteins of the Wnt/β-catenin pathway, which is intimately involved in normal development and the regulation of cancer stem cells (35). LGR5 binds to Wnt, low-density lipoprotein receptor-related protein (LRP) and frizzled (FZD) after interaction with the ligand R-spondin (RSPO); the resulting complex promotes the phosphorylation of GSK-3βSer9 and inhibits the phosphorylation of β-catenin (36). Unphosphorylated β-catenin translocates to the nucleus and interacts with transcription factors, activating the expression of downstream genes such as c-myc and cyclin D1 and ultimately promoting cell proliferation (37). Research has reported that in colorectal cancer cells, the depletion of LGR5 can decrease the expression of c-myc and cyclin D1, which are downstream target genes of the Wnt/β-catenin pathway, and induce apoptosis via an intrinsic apoptosis pathway (38). Therefore, we believe that suppression of LGR5 expression and of the Wnt/β-catenin signaling pathway may be the mechanism by which TCS induces apoptosis in U87 cells. However, understanding the detailed mechanism will require further study.

Further studies of the efficacy of TCS in in vivo models are needed to confirm our findings, although our results have demonstrated that TCS can induce apoptosis and inhibit the invasive/metastatic potential of glioma cells; thus, this study has revealed a novel concept for the treatment of malignant gliomas.